Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MonoFIX-VF, a new mono-component factor IX concentrate: a single-centre continuous-infusion study.

G Evans1, M Collett, N Came

  • 1Haemophilia Centre, Kent and Canterbury Hospital, Canterbury, Kent, UK. gillian.evans@ernt.nhs.uk

Haemophilia : the Official Journal of the World Federation of Hemophilia
|August 30, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acceptability of air cleaning units on inpatient wards: help for infection control or hindrance for ward occupants?

The Journal of hospital infection·2024
Same author

The barriers to linkage and retention in care for women living with HIV in an high income setting where they comprise a minority group.

AIDS care·2019
Same author

Principles of haemophilia care: The asia pacific perspective. Response.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Principles of haemophilia care: The Asia-Pacific perspective.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Echocardiography has minimal yield and may not be warranted in Staphylococcus aureus bacteremia without clinical risk factors for endocarditis.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2015
Same author

Medical co-morbidities and practice.

Haemophilia : the official journal of the World Federation of Hemophilia·2014
Same journal

Male Range of Motion Norms in the Haemophilia Joint Health Score Underrepresent the Severity of Joint Damage in Females.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Physical Activity and Sedentary Behaviour in Children With Haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Ten-year Demographic and Clinical Characterisation of People With Haemophilia: The Colombian Registry Experience.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Exploratory Claims-Based Assessment of Diagnosed and Potentially Undiagnosed von Willebrand Disease in Japan.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Use of an Oral Health-Related Quality of Life Instrument to Measure Unmet Dental Care Needs in Adults With Inherited Bleeding Disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Clinical Factors for Predicting Synovial Hypertrophy in Early Haemophilic Arthropathy on Prophylaxis: A Cross-Sectional Study of Patient- and Joint-Level Analyses Using Musculoskeletal Ultrasound.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
See all related articles

MonoFIX-VF is now the preferred treatment for factor IX deficiency in Australia. This study confirms its safety and effectiveness in managing bleeding episodes and surgical procedures in patients with haemophilia B.

Area of Science:

  • Hematology
  • Pharmacology

Background:

  • Factor IX deficiency, also known as haemophilia B, requires effective clotting factor replacement therapy.
  • Prothrombinex-HT was previously the standard treatment for factor IX deficiency in Australia.
  • MonoFIX-VF, a monocomponent factor IX concentrate, has been introduced as a new treatment option.

Purpose of the Study:

  • To assess the haemostatic efficacy and safety of MonoFIX-VF in patients with factor IX deficiency.
  • To evaluate MonoFIX-VF's performance in managing bleeding episodes and surgical procedures.

Main Methods:

  • A study was conducted involving four subjects with factor IX deficiency.
  • MonoFIX-VF was administered via continuous infusion to treat 10 bleeding episodes.
  • Treatment included five surgical procedures.

Related Experiment Videos

Main Results:

  • MonoFIX-VF demonstrated a safe and effective haemostatic effect across all treated episodes.
  • The treatment was well-tolerated by the subjects.
  • Successful management of bleeding and surgical interventions was observed.

Conclusions:

  • MonoFIX-VF is a safe and effective treatment for patients with haemophilia B.
  • Continuous infusion of MonoFIX-VF provides adequate haemostasis for bleeding episodes and surgical procedures.
  • MonoFIX-VF represents a valuable therapeutic option for factor IX deficiency.